Ganfort (bimatoprost;timolol)
- Region
- 🇪🇺 EU
- Active substance
- bimatoprost;timolol
- Company
- AbbVie Deutschland GmbH & Co. KG
- Status
- Authorised
- Therapeutic area
- Glaucoma, Open-Angle; Ocular Hypertension
- EU approval
- Fri 19 May 2006
- Application
- EMEA/H/C/000668
- ATC
- S01ED51
- Official record
- www.ema.europa.eu
Indication
Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
Regulatory milestones
No milestones recorded in the last year.
Follow Ganfort
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.